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BACKGROUND: In Italy, cervical cancer screening programmes actively invite women aged 25–64 years. Programmes are hindered
by low participation.
METHODS: A sample of non-responder women aged 35–64 years, belonging to three different programmes (in Rome, Florence and
Teramo), was randomly split into four arms: two control groups received standard recall letters to perform either
Pap-test (first group) or human papillomavirus (HPV) test (second group) at the clinic. A third arm was sent letters offering a
self-sampler for HPV testing, to be requested by phone, whereas a fourth group was directly sent the self-samplers home.
RESULTS: Compliance with standard recall was 13.9% (N619). Offering HPV test at the clinic had a nonsignificant effect on compliance
(N616, relative risk (RR)¼1.08; 95% CI¼0.82–1.41). Self-sampler at request had the poorest performance, 8.7% (N622,
RR¼0.62; 95% CI¼0.45–0.86), whereas direct mailing of the self-sampler registered the highest compliance: 19.6% (N616,
RR¼1.41; 95% CI¼1.10–1.82). This effect on compliance was observed only in urban areas, Florence and Rome (N438, RR¼1.69;
95% CI¼1.24–2.30), but not in Abruzzo (N178, RR¼0.95; 95% CI¼0.61–1.50), a prevalently rural area.
CONCLUSIONS: Mailing self-samplers to non-responders may increase compliance as compared with delivering standard recall letters.
Nevertheless, effectiveness is context specific and the strategy costs should be carefully considered.
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Testing for human papillomavirus (HPV) DNA in the cervix has
been shown to be an effective mean for cervical cancer prevention
in large population trials carried out in different countries with
huge differences in social, cultural and economical background
(Bulkmans et al, 2007; Naucler et al, 2007; Sankaranarayanan
et al, 2009; Ronco et al, 2010). Human papillomavirus test is
more sensitive than conventional Pap-test (Cuzick et al, 2006,
2008), giving a longer protection in case of negative results, and
the overdiagnosis can be controlled at least in women aged
35 years and older (Bulkmans et al, 2007; Naucler et al, 2007;
Sankaranarayanan et al, 2009; Ronco et al, 2010).
Even if an increase in test sensitivity is welcome, this is not the
main problem in cervical cancer prevention. In fact, in most
industrialised countries, the majority of invasive cancers occurs in
never-screened or under-screened women (van der Graaf et al,
1988; Ciatto et al, 1993; Janerich et al, 1995; Sasieni et al, 1996;
Sung et al, 2000; Leyden et al, 2005; Morrell et al, 2005; Bos et al,
2006; Ingemann-Hansen et al, 2008). As a consequence, the
heaviest and most immediate impact on cervical cancer prevention
can be obtained only by improving the test coverage (IARC, 2005;
Arbyn et al, 2008).
In Italy, more than two-thirds of the female population aged
25–64 years is covered by screening programmes that actively invite
the whole target population by mail every 3 years. Compliance with
invitation is low, about 40% (Ronco et al, 2008). Nevertheless, the
test coverage is estimated to be quite high, 470% (data from
National Health Interview (ISTAT, 2006) and PASSI study (PASSI,
2009)), owing to opportunistic testing by private and public
gynaecologists. Furthermore, wide variations in test coverage are
observed among regions, ranging from 48 to 88% (ISTAT, 2006).
The use of HPV DNA test as primary screening test allows for
the introduction of self-sampling (Wright et al, 2000; Nobbenhuis
et al, 2002; Sanner et al, 2009; Go ¨k et al, 2010), whereas
conventional Pap-test requires sampling to be performed by a
health professional. The opportunity of a home, self-collected
sample, opens the chance to remove some of the barriers that may
discourage women from participating to screening programmes or
performing Pap-test. Self-sampling is less time consuming and
invasive as compared with tests performed at a clinic. It allows for
privacy, reduces discomfort and women know nobody would have
to handle their body.
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introducing a self sampler device using different strategies.
POPULATION AND METHODS
Setting
The study was performed within three organised screening
programmes from three different Italian regions: Florence
(Tuscany), Rome southern city (Lazio) and Teramo (Abruzzo).
In these areas, programmes actively invite all the resident female
population aged 25–64 years for a Pap-test every 3 years.
Study population
Women aged 35–65 years who had been invited by the screening
programme in the previous months and had failed to respond were
eligible for mail recall. Each programme has a different strategy for
recall: in Florence, recalls are sent to all non-responding women
after invitations for a whole district are completed, which is to say
after a period of at least 3 months and not more than 5 months.
In Rome and Teramo, recalls are automatically mailed to non-
responders 3 months after the invitation.
Study design
A random sample of 2480 eligible women was randomly assigned
to one of the following arms (Figure 1):
(1) two control arms with a standard invitation letter to perform
either a Pap-test (a) or an HPV test (b) at the clinic on a
pre-fixed date;
(2) two intervention arms:
(2.1) a group was offered the opportunity to receive the
self-sampler device (PantaRhei Devices, Zeist, the
Netherlands) (Brink et al, 2006) (by mail or picking it
up at the clinic). If interested, women had to call a free
toll number.
(2.2) another group was directly sent the self-sampler,
announced by a letter a week before.
The lists of eligible women were provided by the centres. When
known, women of the same household were identified with a flag and
randomised as a unique item to the same arm (we decided
not to account for this in the analysis owing to the extremely
low number of these couples). Random sampling and arm assign-
ment were performed centrally by the coordinating centre (Rome)
using STATA 8.2 (StataCorp, College Station, TX, USA) and putting
as seed for random number generator the first number drawn by the
most recent National Lottery: four consecutive samples of the pre-
determined size of independent statistical units were drawn and
assigned to the corresponding arm. Couples of women resident in
the same address were randomised as a single statistical unit.
The planned sample size was 200 women per arm per centre.
This would allow for 80% power to detect, with 95% confidence, a
7% increase in compliance, in the hypothesis of 15% compliance in
the control arm. Sampling started in Rome, with the very sample
size as previously planned (800). As a result, extra self-sampler
boxes were available for the study in Florence, in which the sample
size was slightly increased (235 per arm¼940 total). In Abruzzo,
we later planned an additional fifth arm, slightly decreasing
the number of women in the four arms (180 per arm). Actually
the fifth arm was implemented as a separate trial, a few months
after this study, owing to the earthquake that destroyed part of the
Abruzzo region in April 2009.
Description of the intervention
In the two control arms, the intervention was only the recall letter
inviting for a Pap smear (arm (a)) or an HPV test (arm (b)) at a
prefixed date at the clinic.
In the arm with the self-sampler at request, we mailed a letter
inviting women to dial a free-toll number to receive the
self-sampling device and an information leaflet on HPV test and
cervical cancer. We offered women two opportunities: to either
Screening programme
 invitation
Direct mailing
self-sampler arm 622
Compliant
not eligible (45%)
Letter announcing
the self-sampler 
Mailing of the kit 616
Non-compliant
eligible (65%)
Invitation letter to
phone to call center to
receive self-sampler 622
Pap-test 86
1 week
Standard recall
 619
Recall for HPV
at the clinic 617
HPV 77
Randomisation
2480
Six excluded because
the self-sampler box
was erroneously
not mailed
Pap-test 15 HPV 36 Pap-test 18 HPV 103 Pap-test 18
One excluded
because had
a Pap before
randomisation
9
0
 
d
a
y
s
ASC-US+ 1 ASC-US+ 0 ASC-US+ 0 ASC-US+ 0 HPV+ 5 HPV+ 6 HPV+ 22
Figure 1 Flowchart of the study design. ASC-USþ, women with cytology atypical squamous cells of unknown significance or more severe; HPVþ,
women with high-risk HPV DNA test positive.
Participation to self-sampled HPV testing
P Giorgi Rossi et al
249
British Journal of Cancer (2011) 104(2), 248–254 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
shave the device shipped home or pick it up by themselves at the
clinic. The self-sampler box contained the following items:
  a presentation letter;
  a leaflet about HPV test and cervical cancer prevention;
  the informed consent form to perform the test and to be
contacted by phone in case of positivity;
  the self-sampler device;
  the instructions for the device use;
  a tube and a pre-paid envelope to mail of the sample; and
  a short questionnaire asking the approximate date of the latest
Pap-test, questions about the sampling (if it was easy, annoying,
embarrassing) and the date of sampling.
In the arm with the direct mailing, we sent an alerting letter
explaining that the local Public Screening Program would provide
women with a box containing a self-sampler device completely
free. After 1 week, we shipped the box, containing the same items
listed above.
Questionnaires slightly differed among centres owing to length
constrains and local priorities. In this study, we analyse only the
questions that were almost identical in the three versions: date
of women’s latest Pap-test, reason for non-compliance with the
screening programme (only Rome and Florence), questions about
the self-sampling performance (pain, embarrassment, feasibility),
what was mostly appreciated in the self-sampling (doing it by
themselves, privacy, absence of a doctor, absence of speculum),
which kind of sampling was preferred (i.e., self-performed or
carried out at the clinic).
Management of HPV-positive women
All women who resulted in being HPV positive were contacted by
phone and letter to propose a counselling on HPV and cervical
cancer risk and a colposcopy. If the colposcopy was positive, a
biopsy was taken, and if colposcopy was negative, women were
suggested to undergo control with Pap-test within a year’s time.
Outcome
The main outcome we took into consideration was women’s
participation in screening: all women who accepted to perform a
test in the screening programme within 3 months from the first
letter mailing were considered a success.
A secondary outcome was the impact on cervical cancer
screening coverage, measured as the number of women never-
covered or under-covered (latest test performed longer than
3 years earlier) for whom we obtained a cervical sample.
Other secondary outcomes were HPV positivity rate and
detection rate for CIN2þ in the intervention arm.
Laboratory methods
Samples pretreatment When samples arrived at the laboratory,
they were centrifuged at 500g for 10min. Supernatants were
discarded and pellets suspended in 1ml of STM (Specimen
Transport Medium; Qiagen, Hilden, Germany). Before performing
Hr-Hybrid Capture 2 (HC2), 200ml aliquots were stored at  801C.
HPV testing and evaluation of sample adequacy Highrisk (HR)
HPV was evaluated by HC (Qiagen), using only the B probe mix,
which is specific for 12 HR HPV types: 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59 and one probably carcinogenic HPV type: 68
(Bouvard et al, 2009). The recommended positivity threshold of
1pgml
 1 (equivalent to 5000 viral copies per test well) was used as
a cutoff control value, and all samples with an RLU/Control ratio
X1.00 were considered HR-HPV positive.
In Florence, all HC2-negative samples were further analysed
to evaluate sample adequacy. DNA was extracted from 200mlo f
un-denaturated STM samples with QIAamp DNAMini kit (Qiagen)
according to the manufacturer’s instruction. Amplification of the
human b-globin gene was performed using GH20-PC04 primers
(268-bp amplicon length) (Bauer et al, 1992). One HPV-negative
sample was included in each batch of extraction to exclude any
contamination. Polymerase chain reaction products were run on
2% ethidium bromide-stained agarose gels and visualised by
ultraviolet light.
Analysis
We adopted an intention-to-treat analysis: women were consi-
dered as participating, independently of the randomisation arm,
if they provided any kind of sample (Pap smear, STM or
self-collected liquid sample), in any setting (home or screening
clinic).
We report the relative risk (RR) of having a test comparing each
intervention arm with the two controls. Participating centres
samples were pooled if there was no heterogeneity.
We used the information collected with questionnaires to
calculate the impact on population coverage of each strategy
according to the following formula:
ððunder-coveredrespondentsÞ=ðtotalrandomisedsampleÞÞ
 ðproportionof nonrespondersatfirstinvitationÞ:
RESULTS
Nine hundred and fifty-one women were randomised in Florence,
800 in Rome and 729 in Abruzzo. Six women were excluded after
randomisation in the direct mailing arm because the kit was not
mailed owing to a logistical mistake and one was excluded because
she had had a Pap-test in the screening programme before
randomisation, but it had been notified to the coordinating centre
just after the study started.
Table 1 shows the compliance by arm and by centre.
Effect on compliance
The compliance with standard recall was 13.9%, similar to that
obtained with a standard letter inviting women to perform HPV
test at the clinic (14.9%). The group which received the self-
sampler on demand had a poorer performance as compared
with the standard recall letter arm, RR 0.62 (95% CI¼0.45–0.86)
with no differences among centres. The self-sampler direct
mailing strategy had, on average, a higher performance and
increased compliance by 40% (RR 1.41, 95% CI¼1.10–1.82) with
respect to standard recall, but it showed a border line significant
heterogeneity among centres. In fact, the positive effect was
detectable only in urban areas, Rome and Florence, whereas in
Abruzzo, a prevalently rural, small town area, no positive effect
was detected.
Positivity rate and detection rate
In the direct mailing arm, according to the dates reported in
the questionnaires, the median time elapsed from the sampling
and the laboratory check in for the specimen was 4 days and
only one sample took longer than 1 week (8 days). Nevertheless,
in Abruzzo, where the kits were mailed in July with very high
environmental temperatures, some specimens looked conta-
minated by a strong bacterial growth and two samples were
unsatisfactory.
The overall positivity rate among the self-collected samples in
the direct mail arm was 21.8% (22 out of 101). All but two women
accepted to perform a colposcopy (91%) and no CIN2þ was
found. The positivity rate in the HPV control arm was 6.5% (5 out
of 77), and the difference was statistically significant (P¼0.006).
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was one out of 86 (1.2%). The woman had a colposcopy and no
CIN2þ was found.
Acceptability of the self-sampling device
We collected 147 questionnaires. The most frequent reason for
failing to comply with previous screening invitation was recent
Pap-test (40.6%). No woman declared that Pap-test is not
important and only two of them declared that they did not
perform the test because they were embarrassed (Table 2A).
Table 2B shows the answers about the sampling: 88.3% (128) of
women declared that the sampling was easy, only two reported that
it was annoying and two reported that it was embarrassing. The
most checked reasons for which they appreciated the self-sampling
were ‘to do the sampling by myself’ (57.6%) and ‘privacy’ (49.3%).
In the open answer questions, some women expressed concerns
about the quality of self-collected samples, and six of them
complained about broken devices (in all cases the sample was
taken and analysed). No woman reported concerns about having
the HPV viral test instead of the cytological test, nor about the way
of infection.
Impact on population coverage
Only six women (4.1%) referred to never having had a Pap-test
before and five did not remember (3.4%). Among the others,
12 (8.2%) had had a test longer than 5 years before, and 45 (30.8%)
had had it between 3 and 5 years before.
The impact on coverage was computed only for Florence and
Rome, the very places where a definite gain in coverage has been
proved; and for the arm in which an increase in compliance as
compared with standard recall has been observed: the direct
mailing arm. Out of 91 women responding to the direct mailing of
the kit in Florence and Rome, four had never had a Pap-test before
and 30 were under-covered, that is, they had undergone a test
longer than 3 years earlier, whereas the rest of women had had a
Pap-test within 3 years. The proportion of not- or under-covered
women on the total randomised sample is 34 out of 438 (7.8%).
This proportion must be applied to the population that had not
responded to first invitation, that is, the eligible population for the
trial. This proportion in Florence and Rome was 65%. Accor-
ding to the formula proposed in the Population and Methods
section, the impact of direct mailing on population coverage would
be: (34/438) 0.65¼þ5.1% (95% CI¼3.6–7.1). If we consider
Table 1 Compliance by arm and type of test
Intervention
Invited
women
Test
HPV Pap-test
Compliance
(%)
RR vs
Pap-test 95% CI
Test for
heterogeneity
RR vs
HPV 95% CI
Test for
heterogeneity
Total
Standard recall 619 0 86 13.9 1 0.93 (0.71–1.22) 0.27
Self-sampling on demand 622 36 18 8.7 0.62 (0.45–0.86) 0.92 0.58 (0.42–0.80) 0.22
Self-sampling direct mailing 616 103 18 19.6 1.41 (1.10–1.82) 0.11 1.32 (1.03–1.68) 0.01
HPV at the clinic 616 77 15 14.9 1.08 (0.82–1.41) 0.27 1
Florence
Standard recall 238 0 34 14.3 1 0.76 (0.50–1.14)
Self-sampling on demand 240 12 9 8.8 0.61 (0.37–1.02) 0.47 (0.29–0.76)
Self-sampling direct mailing 238 45 8 22.3 1.56 (1.05–2.31) 1.18 (0.83–1.69)
HPV at the clinic 234 40 4 18.8 1.32 (0.87–1.98) 1
Rome
Standard recall 200 0 20 10.0 1 1.43 (0.74–2.75)
Self-sampling on demand 200 12 2 7.0 0.70 (0.36–1.35) 1.0 (0.49–2.04)
Self-sampling direct mailing 200 36 2 19.0 1.90 (1.15–3.15) 2.71 (1.52–4.85)
HPV at the clinic 200 14 0 7.0 0.70 (0.36–1.35) 1
Abruzzo
Standard recall 181 0 32 17.7 1 0.95 (0.61–1.46)
Self-sampling on demand 182 12 7 10.4 0.59 (0.35–1.00) 0.56 (0.33–0.94)
Self-sampling direct mailing 178 22 8 16.9 0.95 (0.61–1.50) 0.90 (0.58–1.41)
HPV at the clinic 182 23 11 18.7 1.06 (0.68–1.64) 1
Abbreviations: CI¼confidence interval; HPV¼human papillomavirus; RR¼relative risk. Values given in bold indicate that RR is significantly different from 1, Po0.05.
Table 2 Answer to questionnaires
(A) Reasons for non-compliance with screening programme
invitation letter
Reasons for non-compliance N %
Recent Pap-test 41 40.6
No time 23 22.8
I did not receive the letter 15 14.9
I was out 7 6.9
I was pregnant 6 5.9
It is embarrassing 2 2.0
I think it is not useful 0 0.0
Other 7 6.9
Total 101 100
(B) Attitudes to self-sampling
Yes
Total
N % N
The sampling was
Easy 128 88.3 145
Annoying 2 1.4 145
Embarrassing 2 1.4 145
I was not sure I had a good sample 17 11.8 144
I appreciated
To do the sampling by myself 83 57.6 144
Not to be undressed in front of a doctor 37 25.2 147
The absence of speculum 45 31.5 143
Privacy 70 49.3 142
Self Clinic
Which sampling method do you prefer N % N %
109 78.4 30 21.6
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sunder-covered those who had had a Pap-test over 5 years earlier,
the impact on compliance would then be 2.2% (95% CI¼1.2–3.7).
DISCUSSION
Our results show that delivering self-samplers may increase
compliance with cervical cancer screening programmes. Even if
the observed heterogeneity was not statistically significant, we
must highlight that a positive effect on compliance was observed
only in Florence and Rome. Many context factors might explain
this difference: there could be cultural and behavioural differences
between urban and rural areas, or there may be more logistical
problems in shipping self-sampler boxes in rural areas owing
to different shape or location of the mail boxes. Finally, in Abruzzo
the trial was performed in mid-July, when compliance with
screening programmes is usually low and decreases as we get
nearer August, when most Italian families are on holidays. In this
period, the additional week needed in the direct mailing arm may
have had a strong negative influence on compliance. This delay in
performing our analysis was owing to the above-mentioned
earthquake hitting the Abruzzo region in April 2009, which halted
all studies for weeks.
We only found one randomised controlled trial comparing the
effect of using the self-sampler instead of the standard recall letter
for conventional cytology on compliance with screening invitation
(Go ¨k et al, 2010).
Some non-randomised trials showed a potential impact to
increase test uptake and feasibility on large scale (Belinson
et al, 2003; Salmero ´n et al, 2003; Sanner et al, 2009; Ogilvie
et al, 2007; Szarewski et al, 2007). Two systematic reviews (Petignat
et al, 2007; Stewart et al, 2007) concluded that the accuracy of
self-sampling-based HPV test makes it suitable as an alternative
mean for cervical screening, and one review affirms (Stewart
et al, 2007) that there is lack of evidence on its impact on
compliance.
Our trial design allowed us to distinguish the effect of offering a
new test, that is, HPV instead of Pap, and the effect of self-
sampling. In fact, we compared the intervention arm to two
different control letters: the standard one, inviting for a Pap-test,
and a similar letter inviting women to an HPV test with the same
modalities. In Rome and Abruzzo, the two controls had the same
performance, but in Florence, the HPV control had an inter-
mediate performance between the standard Pap-test recall letter
and the direct mailing of the self-sampler. Even if the observed
differences are not statistically significant, the results in Florence
may suggest that, at least in that context, part of the increase in
compliance could be owing to the appeal of the new test. It
should be taken into account that Florence was one of the
participating centres in NTCC trial (Ronco et al, 2006). Conse-
quently, the awareness of the population about HPV may be higher
in this area.
Our study was not designed to detect differences in positivity or
detection rate, but the difference in positivity rate between the
control HPV and the direct mailing arm, as well as the low
positivity in the Pap-test arm, suggests that women responding
to self-sampling may be at higher risk of HPV infection.
The difference may be also owing to the sampling technique or
to the transport medium making HCII with self-sampling less
specific than that performed at the clinic. Previous studies
observed only small differences in positivity rate in double
sampling or randomised studies (Belinson et al, 2003; Salmero ´n
et al, 2003; Brink et al, 2006). On the other hand, a higher risk in
non-responding women has been reported in several studies
(Ogilvie et al, 2007). In particular, Go ¨k et al (2010) found a higher
risk in women responding to self-sampling.
We did not face important logistical problems. Few kits were
returned late by the postal provider, and no claims for privacy or
other individual offences came from the women involved. On the
other hand, we had some evidence that very high external
temperature may be a problem for sample conservation during
transport through standard mail.
Acceptability
The test was very well accepted by responding women, and the
majority of them declared to prefer this way of sampling compared
with the clinical sample. Pain and embarrassment were not
problems at all, although some women declared it was not easy or
that they were concerned about having collected the sample
properly. The main reason to prefer self-sampling was the do-it-
yourself opportunity given by the device, but also the less
frequently checked answers, the absence of speculum and the
absence of a doctor, were chosen by a relevant proportion of
women. These results are consistent with previous studies (Anhang
et al, 2005; Waller et al, 2006). The reasons for failing to comply
with screening invitation confirmed what was already known for
Italy: opportunistic screening outside screening programmes is
very widespread and logistical barriers interfere with compliance
(lack of time, failure to receive the letter).
Impact on population coverage
In the self-sampling arms, the proportion of not- or under-covered
women was quite high among those who accepted to perform the
test: according to questionnaires, more than 43% of women had
had a Pap longer than 3 years earlier. According to the National
Health Interview and the PASSI survey (ISTAT, 2006; PASSI, 2009),
in these areas the proportion of not- or under-covered (latest
Pap-test 43 years before) women is much lower: 16% in Rome,
15% in Florence and 25% in Abruzzo. The difference is not
surprising, as the eligible population in our study included only
programme non-responders. The high Pap-test coverage in
Florence and Rome is the effect of widespread opportunistic
screening, both in the public and the private sector (Giorgi Rossi
et al, 2006; ISTAT, 2006; PASSI, 2009). In this urban context, a 5%
increase brings the coverage up to 90%. Considering that this
estimate does not exclude virgins, and permanently sick women,
and only partially accounts for hysterectomies, 90% may be
considered a virtually full coverage.
Nevertheless, a 5% increase in coverage (2% if we only consider
under-covered women with a Pap-test longer than 5 years earlier)
is relevant in terms of public health. An increase in population
Pap-test coverage of 1 or 2% is what has been obtained by most
trials that measured the impact and not only the RR of the
intervention vs control arms (Eaker et al, 2004; Corkrey et al, 2005;
Jensen et al, 2009). The Danish Health Technology Assessment of
cervical cancer found that an absolute increase in the coverage rate
of 1% equals the risk reduction obtained by reducing the interval
from 3 to 2 years and estimates a gain of 85 life-years each year in
Denmark (Sundhedsstyrelsen et al, 2005).
If the absolute relevance of such a gain in population health is
not questionable, the costs to obtain it must be carefully
considered. In our trial, we had to send out five self-samplers to
get one sample back to be tested. This number goes up to 13 if we
consider the number needed to gain uncovered women to
screening. Low response rate and high population coverage owing
to overlapping of organised and opportunistic screening are
context factors that minimise the advantages and maximise the
costs of direct mailing: we must ship many self-samplers to non-
responders, but only a few under-covered women are the real
target of the intervention. We tried to reduce costs sending
the samplers only to women who were interested and requested it,
but this strategy had a worse participation rate than standard
recall letters. In this trial, we did not investigate self-sampling
strategies that might strongly reduce the workload for midwives,
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sthat is, not targeted only to non-responders, but also to all the
target population.
CONCLUSIONS
Self-sampling for HPV testing is acceptable to women and
mailing a device for HPV DNA self-collection to non-responders
to cervical cancer screening may increase compliance as
compared with standard recall letters. Nevertheless, effec-
tiveness is context specific. On top of this, the strategy is very
expensive in terms of number of self-samplers needed per screened
woman.
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